Positive News SentimentPositive NewsNASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free VERV Stock Alerts $5.24 -0.04 (-0.76%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$5.17▼$5.4950-Day Range$5.24▼$13.3852-Week Range$5.16▼$21.42Volume1.27 million shsAverage Volume1.40 million shsMarket Capitalization$439.95 millionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verve Therapeutics alerts: Email Address Verve Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside529.8% Upside$33.00 Price TargetShort InterestBearish29.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.54Based on 2 Articles This WeekInsider TradingAcquiring Shares$475,760 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.73) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector665th out of 931 stocksPharmaceutical Preparations Industry309th out of 428 stocks 3.4 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Verve Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.40% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 6.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 3.1 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Verve Therapeutics this week, compared to 4 articles on an average week.Search Interest22 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have bought 3,713.71% more of their company's stock than they have sold. Specifically, they have bought $475,760.00 in company stock and sold $12,475.00 in company stock.Percentage Held by Insiders19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verve Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.73) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Verve Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsBanking Apocalypse Ahead: Secure Your Savings Today!During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. We warned about 484 — an accuracy rate of 99.8% Now, I have a new warning.See what it is here! About Verve Therapeutics Stock (NASDAQ:VERV)Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More VERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Stock News HeadlinesMay 17, 2024 | insidertrades.comAndrew D. Ashe Buys 76,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockMay 19, 2024 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Down 3.6% May 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 11, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong FinancialsMay 10, 2024 | finance.yahoo.comAnalysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This WeekMay 9, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)May 9, 2024 | markets.businessinsider.comBuy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth PotentialMay 9, 2024 | finance.yahoo.comVerve Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amid Progress and Promising PipelineMay 8, 2024 | msn.comVerve Therapeutics GAAP EPS of -$0.59 beats by $0.12, revenue of $5.7M beats by $3.45MMay 8, 2024 | investorplace.comVERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102May 3, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | wsj.comGV’s Newest Life Sciences General Partner Pursues Precision TreatmentsApril 18, 2024 | msn.comVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77April 11, 2024 | benzinga.comTop 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterApril 9, 2024 | markets.businessinsider.comBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated RecoveryApril 9, 2024 | msn.comA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest TwistApril 6, 2024 | fool.comAfter a Serious Setback, Is Verve Therapeutics a Buy?April 3, 2024 | msn.comGene Editing Experiment Halted as Patient Gets Weird Side EffectsApril 3, 2024 | seekingalpha.comVerve Therapeutics: An Update On Human CRISPRApril 3, 2024 | seekingalpha.comVerve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment PauseSee More Headlines Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/29/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees255Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$55.00 Low Stock Price Target$15.00 Potential Upside/Downside+529.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,070,000.00 Net Margins-1,226.51% Pretax Margin-1,224.13% Return on Equity-37.35% Return on Assets-29.31% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$11.76 million Price / Sales37.41 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book0.72Miscellaneous Outstanding Shares83,960,000Free Float67,760,000Market Cap$439.95 million OptionableOptionable Beta1.94 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sekar Kathiresan M.D. (Age 51)Co-Founder, CEO & Director Comp: $973.25kMs. Allison Dorval (Age 48)CFO & Principal Accounting Officer Comp: $711.76kDr. Andrew M. Bellinger M.D. (Age 46)Ph.D., Chief Scientific Officer Comp: $758.29kMr. Andrew D. Ashe J.D. (Age 57)President, COO & General Counsel Comp: $703.85kDr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Joan Nickerson M.B.A. (Age 55)Chief Administrative Officer More ExecutivesKey CompetitorsKeros TherapeuticsNASDAQ:KROSProtagonist TherapeuticsNASDAQ:PTGXNewAmsterdam PharmaNASDAQ:NAMSStructure TherapeuticsNASDAQ:GPCREvotecNASDAQ:EVOView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 16,669 shares on 5/20/2024Ownership: 0.020%Ikarian Capital LLCSold 41,300 shares on 5/17/2024Ownership: 0.000%Redmile Group LLCSold 114,154 shares on 5/16/2024Ownership: 1.911%California State Teachers Retirement SystemSold 3,912 shares on 5/16/2024Ownership: 0.064%Price T Rowe Associates Inc. MDBought 5,600 shares on 5/15/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions VERV Stock Analysis - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price target for 2024? 8 analysts have issued 12 month price objectives for Verve Therapeutics' shares. Their VERV share price targets range from $15.00 to $55.00. On average, they predict the company's stock price to reach $33.00 in the next year. This suggests a possible upside of 529.8% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2024? Verve Therapeutics' stock was trading at $13.94 on January 1st, 2024. Since then, VERV shares have decreased by 62.4% and is now trading at $5.24. View the best growth stocks for 2024 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) announced its earnings results on Wednesday, May, 8th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.11. The firm had revenue of $5.70 million for the quarter, compared to analyst estimates of $2.11 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 1,226.51%. The firm's revenue for the quarter was up 305.6% compared to the same quarter last year. What ETFs hold Verve Therapeutics' stock? ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS) and ARK Innovation ETF (ARKK) and When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Verve Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.54%), Sumitomo Mitsui Trust Holdings Inc. (3.10%), Nikko Asset Management Americas Inc. (3.09%), Redmile Group LLC (1.91%), Mirae Asset Global Investments Co. Ltd. (0.20%) and Swiss National Bank (0.12%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERV) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
